Development of a child-friendly Continuous Glucose Monitor (CGM): A nanotechnological, minimally-invasive, transdermal sensor for the real-time and painless sensing of interstitial glucose for diabetes

Caura计划开发一种革命性的儿童友好型TRL8实时连续血糖监测设备（CGM），解决当前传统CGM系统相关的主要问题。全球医疗保健系统的糖尿病成本已增长至5580亿英镑（NHS为98亿英镑），其中大部分成本与血糖浓度异常的短期和长期并发症有关。传感器平台代表了CGM技术的一项跨越式创新，提供的解决方案是；*便宜*接近无痛*高度准确，提供实时血糖监测，无需抽血。*儿童及成人均可定期使用。这些颠覆性创新具有巨大的潜力，并将为NHS带来一种高效的CGM设备，既改善了患者的可及性，也改善了疗效，并降低了CGM使用的成本x4。

Caura intends to develop a revolutionary child-friendly TRL8 real-time continuous glucose monitoring device (CGM) that addresses the main issues associated with current conventional CGM systems.The cost of diabetes to healthcare systems has grown to £558bn globally (£9.8bn NHS) , with the majority of costs associated with the short-and long-term complications of abnormal glucose concentrations.The sensor platform represents a step-change innovation in CGM technology, delivering a solution that is;* Cheaper* Near pain-free* Highly accurate and provides real-time glucose monitoring with no blood draw.* Can be utilised regularly by children and adults.These disruptive innovations have significant potential and will result in a highly-effective CGM device for the NHS that both improves patient access, outcomes and reduces costs of CGM use x4.